Search clinical trials for: Biogen

Total 754 results

Vaginal Biome Science
Dr. Aimee Eyvazzadeh, Inc.

Terminated

Effects of Flourish HEC and BioGenesis to Improve Conception

Infertility | Infertility Unexplained

United States
Biogen

Active, not recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis

United States
Pfizer

Terminated

Global Prevalence of ATTR-CM in Participants With HFpEF

Heart Failure With Preserved Ejection Fraction | Transthyretin Amyloid Cardiomyopathy

Spain, United States, Japan, Canada, France, Italy, Poland, United Kingdom
Biogen

Completed

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

Healthy Volunteers

United States
Biogen

Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Multiple Sclerosis, Relapsing-Remitting

Mexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Insel Gruppe AG, University Hospital Bern
Biogen; AUDEERING GMBH

Completed

Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers (COMMITMENT)

Multiple Sclerosis

Switzerland
Eisai Inc.
Biogen

Active, not recruiting

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)

Early Alzheimer's Disease

United States, Spain, Korea, Republic of, China, United Kingdom, Australia, Canada, France, Germany, Italy, Japan, Russian Federation, Singapore, Sweden
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
Biogen

Terminated

Study of Diroximel Fumarate in the Real-World Setting

Relapsing Forms of MS

United States
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Eli Lilly and Company
Incyte Corporation

Terminated

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) (SLE-BRAVE-X)

Systemic Lupus Erythematosus

United States, China, France, Czechia, Taiwan, Hungary, Belgium, Australia, Korea, Republic of, Serbia, Mexico, Poland, Italy, United Kingdom, Germany, Spain, Japan, South Africa, Austria, Russian Federation, Israel, India, Argentina, Croati... and more
Biogen

Terminated

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (EXPER-CA/IL)

Relapsing Forms of MS

Israel
Biogen

Withdrawn

802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-1)

Trigeminal Neuralgia
Biogen

Withdrawn

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-2)

Trigeminal Neuralgia
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Biogen

Completed

A Real-world Study of Imraldi® Use (PROPER)

Arthritis, Rheumatoid (RA) | Arthritis, Psoriatic (PsA) | Crohn's Disease (CD) | Colitis, Ulcerative (UC) | Axial Spondyloarthritis (axSpA)

Italy, United Kingdom, Germany, Belgium, Spain, Ireland
Biogen

Completed

MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study

Multiple Sclerosis (MS)

United States
Biogen

Completed

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

Parkinson's Disease

Belgium, United States, United Kingdom, Netherlands
Biogen

Completed

Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis (DigiToms)

Multiple Sclerosis

France
Biogen

Terminated

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

Alzheimers Disease

United States
Biogen

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
Biogen

Completed

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteer

United States
Biogen

Completed

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Healthy Volunteer

United States
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Biogen

Completed

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Healthy Volunteers

United States
Biogen

Completed

Study of BIIB091 Formulations in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Completed

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Healthy Volunteer

United States
Biogen
Eisai Co., Ltd.

Completed

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Healthy Volunteers

United States
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
University Hospital Inselspital, Berne
Biogen

Terminated

Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System (MSPT)

Multiple Sclerosis | Clinically Isolated Syndrome

Switzerland
Institut National de la Santé Et de la Recherche...
Biogen; Ionis Pharmaceuticals, Inc.

Completed

Integrated Functional Evaluation of the Cerebellum (CERMOI)

Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 7

France
Biogen

Completed

MS PATHS Normative Sub-Study

Healthy Volunteer

United States, Germany, Spain
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS)

X-Linked Retinitis Pigmentosa

United States, France, United Kingdom, Finland, Netherlands, Germany, Canada
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of Choroideremia Study (NIGHT)

Choroideremia

Finland, United States, Canada, Denmark, Netherlands, Germany, United Kingdom, Brazil, France
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19

Severe COVID-19

Israel
Biogen

Terminated

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

Multiple Sclerosis

United States, Italy, Switzerland, United Kingdom, Czechia, France
Vascular Biogenics Ltd. operating as VBL Therapeutics
GOG Foundation

Completed

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL)

Recurrent Platinum Resistant Ovarian Cancer

United States, Israel, Japan, Poland, Spain
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
Eli Lilly and Company
Incyte Corporation

Completed

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) (BRAVE II)

Systemic Lupus Erythematosus

United States, Spain, Korea, Republic of, Serbia, Poland, France, Italy, Japan, South Africa, India, Argentina, Chile, Philippines, Romania, Colombia
Louisiana State University Health Sciences Center...
Biogen

Completed

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
John Levine
Biogen

Completed

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Acute Graft Versus Host Disease

United States
Biogen

Completed

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study (PERFUSE)

Arthritis, Rheumatoid | Crohn's Disease | Arthritis, Psoriatic | Colitis, Ulcerative | Spondylitis, Ankylosing

France
Biogen

Completed

Plegridy Observational Program (POP)

Relapsing Forms of Multiple Sclerosis

United States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
M.D. Anderson Cancer Center
Biogen; CTI BioPharma

Completed

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Lymphoma

United States
University of Rochester
Takeda; Biogen

Completed

Wearable Assessments in the Clinic and Home in PD (WATCH-PD)

Parkinson Disease

United States

Search clinical trials for: Biogen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations